Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables (2022 - 2025)

Historic Receivables for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $232000.0.

  • Amylyx Pharmaceuticals' Receivables fell 8732.93% to $232000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $232000.0, marking a year-over-year decrease of 8732.93%. This contributed to the annual value of $547000.0 for FY2024, which is 9865.1% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Receivables stood at $232000.0, which was down 8732.93% from $203000.0 recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Receivables registered a high of $40.6 million during Q4 2023, and its lowest value of $137000.0 during Q3 2022.
  • Over the past 4 years, Amylyx Pharmaceuticals' median Receivables value was $4.2 million (recorded in 2024), while the average stood at $12.8 million.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 2139854.01% in 2023, then tumbled by 9865.1% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Receivables (Quarter) stood at $15.8 million in 2022, then skyrocketed by 156.55% to $40.6 million in 2023, then crashed by 98.65% to $547000.0 in 2024, then tumbled by 57.59% to $232000.0 in 2025.
  • Its last three reported values are $232000.0 in Q3 2025, $203000.0 for Q2 2025, and $400000.0 during Q1 2025.